公开(公告)号：US20240277841A2

公开(公告)日：2024-08-22

申请号：US18256916

申请日：2021-12-10

申请人： Purdue Research Foundation

发明人： Xiaoping BAO ,  Qing DENG ,  Yun CHANG ,  Ramizah MOHD SABRI

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/435 ,  C12N5/0787 ,  C12N15/85

CPC分类号： A61K39/461 ,  A61K39/4631 ,  A61P35/00 ,  C07K14/43522 ,  C12N5/0642 ,  C12N15/85 ,  C12N2501/125 ,  C12N2501/15 ,  C12N2501/165 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/385 ,  C12N2506/03 ,  C12N2800/107

摘要： The present disclosure relates to a stage-specific process for manufacturing a population of neutrophils, such as chimeric antigen receptor-expressing (CAR-expressing) neutrophils (e.g., T cells and natural killer (NK) cells), from human pluripotent stem cells (hPSCs) using defined media and related compositions, kits, and methods of use (e.g., targeted cancer immunotherapy). Stage-specific processes for generating neutrophils and chimeric antigen receptor (CAR) neutrophils from human pluripotent stem cells (hPSCs) using chemically defined, feeder-free platforms and stage-specific morphogens; cell lines; pharmaceutical compositions; a method of treating cancer; and a kit are within the scopes of this disclosure.

公开(公告)号：US20240024473A1

公开(公告)日：2024-01-25

申请号：US18256916

申请日：2021-12-10

申请人： Purdue Research Foundation

发明人： Xiaoping BAO ,  Qing DENG ,  Yun CHANG ,  Ramizah MOHD SABRI

IPC分类号： A61K39/00 ,  C12N5/0787 ,  C12N15/85 ,  A61P35/00 ,  C07K14/435

CPC分类号： A61K39/461 ,  C12N5/0642 ,  C12N15/85 ,  A61K39/4631 ,  A61P35/00 ,  C07K14/43522 ,  C12N2800/107 ,  C12N2506/03 ,  C12N2501/22 ,  C12N2501/15 ,  C12N2501/165 ,  C12N2501/125 ,  C12N2501/26 ,  C12N2501/385 ,  C12N2501/2303 ,  C12N2501/2306

摘要： The present disclosure relates to a stage-specific process for manufacturing a population of neutrophils, such as chimeric antigen receptor-expressing (CAR-expressing) neutrophils (e.g., T cells and natural killer (NK) cells), from human pluripotent stem cells (hPSCs) using defined media and related compositions, kits, and methods of use (e.g., targeted cancer immunotherapy). Stage-specific processes for generating neutrophils and chimeric antigen receptor (CAR) neutrophils from human pluripotent stem cells (hPSCs) using chemically defined, feeder-free platforms and stage-specific morphogens; cell lines; pharmaceutical compositions; a method of treating cancer; and a kit are within the scopes of this disclosure.